Zymeworks Inc. (NYSE: ZYME) came out with new developments Monday.
The Vancouver, B.C.-based company, a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the selection of an abstract highlighting updated single agent data from the Phase 1 clinical trial evaluating the HER2 targeted bispecific antibody, ZW25, in patients with HER2 expressing solid tumors for a mini oral presentation at the ESMO Asia 2019 Congress, taking place and the end of this week in Singapore.
The presentation, entitled “Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumors,” is scheduled for Friday November 22 at 3:30 pm SGT (local Singapore Time) during the mini oral session Developmental and Precision Medicine in room 311. The presentation number is 61O.
Zymeworks’ Phase 1 study has three parts. From part one of the study (the dose-escalation phase), the recommended single-agent dose was determined to be 20 mg/kg once every two weeks or 10 mg/kg weekly.
In the second part of the study (the cohort expansion phase), additional patients are being enrolled to further assess ZW25’s single-agent tolerability and anti-tumor activity against a variety of cancer types in different settings.
The third part of the study (the combination phase) is underway and evaluating ZW25 in combination with selected chemotherapy agents in gastroesophageal and breast cancer patients with HER2 high or lower HER2 expression levels.
ZW25 is being evaluated in Phase 1 and Phase 2 clinical trials across North America and South Korea
Shares increased in price 29 cents to $36.50